Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 11/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 2/20 | 1.00 |
| ▸ | CDC7 | O00311 | 1/20 | 1.00 |
| ▸ | CHEK1 | O14757 | 1/20 | 1.00 |
| ▸ | AURKA | O14965 | 1/20 | 1.00 |
| ▸ | PDPK1 | O15530 | 1/20 | 1.00 |
| ▸ | DAPK3 | O43293 | 1/20 | 1.00 |
| ▸ | DYRK3 | O43781 | 1/20 | 1.00 |
| ▸ | CACNA1F | O60840 | 1/20 | 1.00 |
| ▸ | RAF1 | P04049 | 1/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 1/20 | 1.00 |
| ▸ | NTRK1 | P04629 | 1/20 | 1.00 |
| ▸ | INSR | P06213 | 1/20 | 1.00 |
| ▸ | CDK1 | P06493 | 1/20 | 1.00 |
| ▸ | FES | P07332 | 1/20 | 1.00 |
| ▸ | CSF1R | P07333 | 1/20 | 1.00 |
| ▸ | LYN | P07948 | 1/20 | 1.00 |
| ▸ | MET | P08581 | 1/20 | 1.00 |
| ▸ | ROS1 | P08922 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bay-549 SCHEMBL4765314 | 1.00 | ROCK2 (1.00) | ROCK2CYP3A4OPRK1CDC7CHEK1 | |
| Bay-549 SCHEMBL29431218 | 1.00 | ROCK2 (1.00) | ROCK2CYP3A4OPRK1CDC7CHEK1 | |
| SCHEMBL4771279 | 0.90 | ROCK2 (0.82) | ROCK2CYP3A4OPRK1CDC7CHEK1 | |
| SCHEMBL25719817 | 0.90 | ROCK2 (0.82) | ROCK2CYP3A4OPRK1CDC7CHEK1 | |
| SCHEMBL4772169 | 0.90 | ROCK2 (1.00) | ROCK2CYP3A4OPRK1CDC7CHEK1 | |
| SCHEMBL13981680 | 0.88 | ROCK2 (1.00) | ROCK2CYP3A4OPRK1CDC7CHEK1 | |
| SCHEMBL13981665 | 0.87 | ROCK2 (0.80) | ROCK2CYP3A4OPRK1CDC7CHEK1 | |
| SCHEMBL2882358 | 0.83 | ROCK2 (0.70) | ROCK2CYP3A4OPRK1CDC7CHEK1 | |
| SCHEMBL2881172 | 0.82 | ROCK2 (0.80) | ROCK2CYP3A4OPRK1CDC7CHEK1 | |
| SCHEMBL8282644 | 0.81 | ROCK2 (0.78) | ROCK2CYP3A4OPRK1CDC7CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4655392-A2 | METHODS FOR SELECTING CULTURED CORNEAL ENDOTHELIAL CELLS | Universiteit Maastricht (NL) | 2025-12-03 | — | — | EP | disclosed |
| CN-118541472-A | Long-term culture of large intestine epithelial cells | ISM有限公司 | 2024-08-23 | — | — | CN | disclosed |
| WO-2024158290-A2 | METHODS FOR SELECTING CULTURED CORNEAL ENDOTHELIAL CELLS | UNIVERSITEIT MAASTRICHT (NL) | 2024-08-02 | — | — | WO | disclosed |
| US-11918581-B2 | Combination therapy comprising JAK pathway inhibitor and rock inhibitor | INCYTE CORPORATION (US) | 2024-03-05 | — | — | US | disclosed |
| CN-117120055-A | Combination therapy comprising a JAK pathway inhibitor and a ROCK inhibitor | 因赛特公司 | 2023-11-24 | — | — | CN | disclosed |
| WO-2023085423-A1 | LONG-TERM CULTURE OF LARGE INTESTINE EPITHELIAL CELLS | ＩＳＭ株式会社 | 2023-05-19 | — | — | WO | disclosed |
| WO-2022265086-A1 | METHOD FOR PRODUCING CEREBRAL CORTICAL CELL PREPARATION DERIVED FROM HUMAN PLURIPOTENT STEM CELLS | 国立大学法人京都大学 | 2022-12-22 | — | — | WO | disclosed |
| US-20220226327-A1 | COMBINATION THERAPY COMPRISING JAK PATHWAY INHIBITOR AND ROCK INHIBITOR | INCYTE CORPORATION | 2022-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11918581-B2 | Combination therapy comprising JAK pathway inhibitor and rock inhibitor | JAK1, ROCK1, JAK3 | ROCK2 4/4885CYP3A4 3751/4885OPRK1 2821/4885 |
| US-20220226327-A1 | COMBINATION THERAPY COMPRISING JAK PATHWAY INHIBITOR AND ROCK INHIBITOR | JAK1, ROCK1, JAK3 | ROCK2 4/4885CYP3A4 3751/4885OPRK1 2821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.